Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9621 posts found.

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

May 18, 2023 Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier

French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …
News

Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer

May 18, 2023 Research and Development Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology

US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic …
News

Nemours Children’s Health selected to conduct first gene therapy for Morquio A syndrome

May 17, 2023 Research and Development Morquio A syndrome, NIH, Nemours Children's Health, Paediatrics, gene therapy

Nemours Children’s Health, based in Delaware, US, has been chosen by the Foundation for the National Institutes of Health (FNIH) …
News

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

May 17, 2023 Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …
News

FDA grants Priority Review for Takeda’s cTTP treatment

May 17, 2023 Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …
News

Astellas and Sony enter collaborative research agreement

May 16, 2023 Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement

Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …
News

LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

May 15, 2023 Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …
News

Relief Therapeutics awarded approval from Swissmedic for new GMP-compliant laboratory

May 15, 2023 Research and Development GMP, Relief Therapeutics, Swissmedic, laboratory

Swiss biopharmaceutical company Relief Therapeutics has announced that its state-of-the-art R&D laboratory in Balerna, Switzerland, has been audited and approved …
News

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

May 12, 2023 Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …
News

Eyenovia announces FDA approval of first ophthalmic spray for mydriasis

May 10, 2023 Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology

Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …
News

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

May 9, 2023 Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …
News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023 Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …
News

Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments

May 4, 2023 Research and Development Cardiology, Vicore Pharma, clinical trials, endothelial dysfunction, organ damage

Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, …
News

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023 Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …
News
cdc-d5nff1slguy-unsplash

FDA approves Pfizer’s pneumococcal conjugate vaccine for infants and children

April 28, 2023 Market Access, Research and Development, Sales and Marketing Ear Nose & throat, FDA, Immunology, Pfizer, Vaccine, pneumococcal vaccine

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) …
News
The Gateway to Local Adoption Series

Latest content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026

BioDuro and CTI Biotechnology in preclinical drug development partnership

May 21, 2026

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

May 21, 2026

NICE recommends sotatercept for pulmonary arterial hypertension

May 20, 2026

Vetter begins construction of new injectable medicines facility

May 20, 2026